| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a … JA Dormandy, B Charbonnel, DJA Eckland, E Erdmann, ... The Lancet 366 (9493), 1279-1289, 2005 | 5363 | 2005 |
| 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and … F Cosentino, PJ Grant, V Aboyans, CJ Bailey, A Ceriello, V Delgado, ... European heart journal 41 (2), 255-323, 2020 | 5064 | 2020 |
| Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial AF Hernandez, JB Green, S Janmohamed, RB D'Agostino, CB Granger, ... The Lancet 392 (10157), 1519-1529, 2018 | 1526 | 2018 |
| Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity K Malmberg, L Rydén, H Wedel, K Birkeland, A Bootsma, K Dickstein, ... European heart journal 26 (7), 650-661, 2005 | 1523 | 2005 |
| The effects of acute and chronic exercise on PGC‐1α, irisin and browning of subcutaneous adipose tissue in humans F Norheim, TM Langleite, M Hjorth, T Holen, A Kielland, HK Stadheim, ... The FEBS journal 281 (3), 739-749, 2014 | 929 | 2014 |
| Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative … M Kosiborod, MA Cavender, AZ Fu, JP Wilding, K Khunti, RW Holl, ... Circulation 136 (3), 249-259, 2017 | 788 | 2017 |
| Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2 JW Haukeland, JK Damås, Z Konopski, EM Løberg, T Haaland, I Goverud, ... Journal of hepatology 44 (6), 1167-1174, 2006 | 731 | 2006 |
| Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study M Kosiborod, CSP Lam, S Kohsaka, DJ Kim, A Karasik, J Shaw, N Tangri, ... Journal of the American College of Cardiology 71 (23), 2628-2639, 2018 | 504 | 2018 |
| Vitamin status in morbidly obese patients: a cross-sectional study ET Aasheim, D Hofsø, J Hjelmesæth, KI Birkeland, T Bøhmer The American journal of clinical nutrition 87 (2), 362-369, 2008 | 471 | 2008 |
| Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial JW Haukeland, Z Konopski, HB Eggesbø, HL von Volkmann, ... Scandinavian journal of gastroenterology 44 (7), 853-860, 2009 | 447 | 2009 |
| Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs … KI Birkeland, ME Jørgensen, B Carstensen, F Persson, HL Gulseth, ... The lancet Diabetes & endocrinology 5 (9), 709-717, 2017 | 392 | 2017 |
| Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. BK Kilhovd, TJ Berg, KI Birkeland, P Thorsby, KF Hanssen Diabetes care 22 (9), 1543-1548, 1999 | 379 | 1999 |
| Impact of ethnicity on gestational diabetes identified with the WHO and the modified International Association of Diabetes and Pregnancy Study Groups criteria: a population … AK Jenum, K Mørkrid, L Sletner, S Vange, JL Torper, B Nakstad, ... European journal of endocrinology 166 (2), 317-324, 2012 | 352 | 2012 |
| The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26 … L Meneghini, SL Atkin, SCL Gough, I Raz, L Blonde, M Shestakova, ... Diabetes care 36 (4), 858-864, 2013 | 347 | 2013 |
| A comparison of the health-related quality of life in patients with diabetic foot ulcers, with a diabetes group and a nondiabetes group from the general population L Ribu, BR Hanestad, T Moum, K Birkeland, T Rustoen Quality of life research 16, 179-189, 2007 | 304 | 2007 |
| Lifestyle changes may reverse development of the insulin resistance syndrome. The Oslo Diet and Exercise Study: a randomized trial PA Torjesen, KI Birkeland, SA Anderssen, I Hjermann, I Holme, P Urdal Diabetes care 20 (1), 26-31, 1997 | 289 | 1997 |
| Effect of rhEPO administration on serum levels of sTfR and cycling performance KI Birkeland, J Stray-Gundersen, P Hemmersbach, J Hallen, E Haug, ... Medicine and science in sports and exercise 32 (7), 1238-1243, 2000 | 271 | 2000 |
| Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2· 4 million patients from 11 countries: The CaReMe CKD study J Sundström, J Bodegard, A Bollmann, MG Vervloet, PB Mark, A Karasik, ... The Lancet Regional Health–Europe 20, 2022 | 249 | 2022 |
| The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study AB Birkenaes, S Opjordsmoen, C Brunborg, JA Engh, H Jonsdottir, ... Journal of Clinical Psychiatry 68 (6), 917-923, 2007 | 241 | 2007 |
| Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl … F Persson, T Nyström, ME Jørgensen, B Carstensen, HL Gulseth, ... Diabetes, Obesity and Metabolism 20 (2), 344-351, 2018 | 238 | 2018 |